SAGE Therapeutics (SAGE) Announces R&D Leadership Transition

Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company’s product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis.

“I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions,” said Barry Greene, Chief Executive Officer of Sage Therapeutics. “Laura has been a relentless advocate for progress in maternal mental health, and we are deeply appreciative of all her contributions and wish her continued success in the future.”

You May Also Be Interested In

• MongoDB (MDB) Reiterated at Market Outperform by Citizens as Investor Day Approaches
• Eagle Plains' Partner Xcite Uranium Intersects Anomalous Radioactivity at Lorado and Commences Drill Program at the Gulch Uranium Project, Saskatchewan
• HSBC Downgrades Braskem (BRKM5:BZ) (BRKMY) to Hold